Alder Biopharmaceuticals Inc., of Bothell, Wash., is set to report data from a randomized, double-blind, placebo-controlled, proof-of-concept trial of ALD403, a genetically engineered monoclonal antibody targeting CGRP, for the prevention of frequent episodic migraine at the American Headache Society meeting in Los Angeles.